Johnson & Johnson Stock: Buy IMAAVY Label Expansion First CAPLYTA Sales Push (NYSE:JNJ)
· seekingalpha.com
Johnson & Johnson (JNJ) keeps a Buy rating as Q2 2026 sales jump and guidance rises.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...